Send to

Choose Destination
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Collaborators (225)

Jasas K, Obyrne K, Houghton B, Hughes B, Lewis C, Links M, Ng S, Parente P, Gauden S, Forget F, Vercauter P, Vansteenkiste J, Canon JL, Cheema P, Vincent M, Murray N, Rothenstein J, Zibdawi L, Bradbury P, Butts C, El-Maraghi R, Bebb D, Acevedo Gaete A, Orellana Ulunque EA, Aren Frontera OR, Mazières J, Renault PA, Robinet G, Cortot A, Hilgers W, Poudenx M, Barlesi F, El Kouri C, Perol M, Lena H, Sabatini M, Pujol JL, Laack E, Schulz C, Brugger W, Faehling M, Reck M, Wolff T, Fischer J, Emde TO, Scholz C, Rueckert A, Kalofonos H, Kotsakis A, Syrigos K, Papazisis K, Zarogoulidis K, Sztancsik Z, Losonczy G, Csanky E, Nechushtan H, Wollner M, Chella A, Bearz A, Chiuri VE, Garassino M, Gianni L, Brighenti M, Ciardiello F, Milella M, Soto Parra H, Sugawara S, Atagi S, Hirashima T, Imamura F, Iwamoto Y, Kanda S, Masuda N, Minato K, Nakagawa K, Niho S, Saka H, Takahashi T, Fujisaka Y, Sakai H, Takahashi K, Baba T, Harada M, Kasahara K, Maeda T, Maemondo M, Okamoto I, Takeda Y, Kobayashi K, Nogami N, Kiura K, Kato T, Hotta K, Park K, Cho EK, Kim HK, Lee JS, Son C, Kim SW, Shin SW, Kim JH, De Langen J, van den Borne B, Kloover JS, van den Heuvel M, van der Leest KH, Aerts JGJV, Hashemi S, Rodriguez Pantigoso W, Bermudez Alfaro V, Jassem J, Mandziuk S, Kowalski D, Chopra A, Tan EH, Chin TM, Soo RA, Stresko M, Demo P, Packan T, Chovanec J, Cohen G, Jacobs C, Rens D, Corral Jaime J, Vidal OJ, Taus Garcia A, Cardenal Alemany F, Garcia Gomez R, Holgado Martin E, Ponce Aix S, Porta Balanya R, Isla Casado D, Majem Tarruella M, Marquez Medina D, Alfaro Lizaso J, Blasco Cordellat A, Sanchez Torres JM, Massuti Sureda B, Sanchez A, Belda Iniesta C, Alvarez R, Hsia TC, Chen YM, Lee KY, Lien YC, Yang CH, Chung CL, Reungwetwattana T, Chewaskulyong B, Geater SL, Goksel T, Harputluoglu H, Artac M, Paydas S, Altundag O, Sencan O, Hicks J, Faivre-Finn C, Talbot T, Telivala B, Hussein M, McCLeod M, Slater D, Uyeki JVH, Waterhouse D, Chen FL, Hao Z, Kelly R, Morgensztern D, Page R, Spira AI, Awad M, Beck JT, Berg AR, Choksi J, Dorroh S, Goldman J, Iannotti N, Kubiak K, Rao S, Chaudhry A, Dalsania CJ, Farrell NJ, Hermann R, Kuzma CS, McIntyre KJ, Mitchell W, Rodriguez E, Sangal A, Smith DA, Zu K, Anderson IC, Behl D, Edenfield WJ, Ghazal H, Giaccone G, Hagenstad CT, Haigentz M Jr, Harper H, Henderson C, Hrinczenko B, Konduri K, Levine M, Martincic D, Pillai RN, Salamat M, Shtivelband M, Singh J, Socoteanu MP, Spigel D, Zorsky P, Ferrarotto R, Gomez J, Horn L, Kendall S, Lawler WE, Gandhi L, Zylla D, Assikis V, McCune S, Bailey S, Le AT, Mai K, Nguyen L.

Author information

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and the Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).



Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.


We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.


Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.


Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC number, NCT02125461 .).

Comment in

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center